The influence of D.D.A.V.P. on the survival of factor VIII in severe haemophiliacs

Thrombosis Research

Volumn 40, Issue 1, 1985, Pages 113-119

  McLellan, D S ^a   Knight, S ^b   McLellan, H G ^a   Wassef, M ^a   Aronstam, A ^a  

^a Lord Mayor Treloar School   (United Kingdom)

^b NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

D.D.A.V.P.; Factor VIII; Haemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; PROTEIN;

BLOOD AND HEMOPOIETIC SYSTEM; CLINICAL ARTICLE; DRUG THERAPY; HEMOPHILIA A; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; THERAPY;

BLOOD TRANSFUSION; DEAMINO ARGININE VASOPRESSIN; DRUG STABILITY; FACTOR VIII; HEMOPHILIA A; HUMANS; KINETICS;

EID: 0022405215     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(85)90355-X     Document Type: Article

References (10)

1. Haemophilia diagnosis and management: progress and problems
2. Therapeutic use of D.D.A.V.P. in haemophilia and von Willebrand's disease
3. The ‘in vivo’ longevity of Antihaemophilic Factor (Factor VIII)
4. The assay of antihaemophilic globulin activity
5. A radial immunodiffusion method for the assay of factor VIII:C antigen (VIII:C Ag) in plasma
6. Electroimmunoassay
7. Structure and function of factor VIII/von Willebrand factor
8. Response of factor VIII/von Willebrand factor to intranasal D.D.A.V.P. in healthy subjects and mild haemophiliacs
9. Specificity in the factor VIII response to vasopressin infusion in man
10. The ‘in vivo’ survival characterists of factor VIII procoagulant antigen (VIII:C Ag) in haemophilia A subjects